Effects of sandostatin and castration on pancreatic carcinogenesis in rats and hamsters

✍ Scribed by M. Meuers; R. A. Woutersen; A. van Garderen-Hoetmer; G. H. Barker; F. H. de Jong; J. A. Foekens; J. G. M. Klijn

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: French
• Weight: 695 KB
• Volume: 50
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910500214

✦ Synopsis

The effects of treatment with the somatostatin analogue Sandostatin, separately and in combination with surgical castration, on the development of azaserine-induced lesions in rat pancreas and N-nitrosobis(2-oxopropyl)amine (BOP)-induced lesions in hamster pancreas were investigated. The animals were divided in 4 groups and treated as follows: (a) controls, injected S.C. with saline solution (0.9% NaCI); (b) orchiectomy directly after the last treatment with carcinogen; (c) Sandostatin (SMS 20 1-995) subcutaneously; (d) orchiectomy followed by treatment with Sandostatin. No significant suppressive effects on plasma EGF or IGF-I concentrations were noted after

Sandostatin treatment, but plasma gastrin levels decreased slightly in the rats, not in the hamsters. In rats, Sandostatin treatment enhanced rather than inhibited growth of acidophilic atypical acinar cell nodules. In hamster pancreas, by contrast, Sandostatin inhibited the development of putative pre-neoplastic ductular lesions. There was no interaction between treatment with Sandostatin and surgical castration. It was concluded that Sandostatin, when administered prophylactically, has an inhibitory effect on the growth of putative pre-neoplastic ductular, but not acinar, lesions.